RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital of Nanchang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06554613, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed EGFR mutation-negative non-small cell lung cancer.

    Inclusion criterion 6

  3. Staged as Stage IV according to the TNM system.

    Inclusion criterion 5

  4. Has not received systemic antitumor treatment, and is intended to receive monotherapy or combined chemotherapy with a PD-1/PD-L1 inhibitor as first-line treatment.

    Inclusion criterion 7

    Within 4 weeks prior to the first administration of the study drug, the subject had undergone major surgery;

    Exclusion criterion 5

    Within 7 days prior to the first administration of the study drug, used strong inhibitors or inducers of CYP3A4.

    Exclusion criterion 6

  5. ECOG score: 0-2 points.

    Inclusion criterion 3

  6. Normal major organ function, that is, meeting the following criteria: (1) Hematological examination criteria must be met: Hb≥90 g/L; ANC≥1.5×10\^9/L; PLT≥80×10\^9/L. (2) Biochemical examination must meet the following criteria: TBIL<1.5×ULN; ALT and AST<2.5×ULN; serum Cr≤1.25×ULN or endogenous creatinine clearance > 45 ml/min (Cockcroft-Gault formula).

    Inclusion criterion 8

    Absolute neutrophil count <1.5×10\^9/L;

    Exclusion criterion 19

    Platelet count <100×10\^9/L;

    Exclusion criterion 20

    Hemoglobin <90 g/L (<9 g/dL);

    Exclusion criterion 21

    If there is no definite liver metastasis, alanine aminotransferase > 3 times the upper limit of normal (ULN); if there is liver metastasis, alanine aminotransferase > 5×ULN;

    Exclusion criterion 22

    If there is no definite liver metastasis, aspartate aminotransferase >3×ULN; if there is liver metastasis, aspartate aminotransferase > 5×ULN;

    Exclusion criterion 23

    If there is no definite liver metastasis, total bilirubin > 1.5×ULN; or with Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastasis, total bilirubin > 3×ULN;

    Exclusion criterion 24

    Creatinine > 1.5×ULN and creatinine clearance <50 mL/min (calculated by the Cockcroft-Gault formula); creatinine clearance is only required if creatinine > 1.5×ULN;

    Exclusion criterion 25

  7. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.

    Exclusion criterion 28

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06554613, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Participants voluntarily enroll in this study and sign an informed consent form, with good compliance and cooperation with follow-up.
  • Age is over 18 years old (including 18 years old) and under 75 years old (including 75 years old).
  • ECOG score: 0-2 points.
  • Expected survival is no less than 3 months.
  • Staged as Stage IV according to the TNM system.
  • Histologically or cytologically confirmed EGFR mutation-negative non-small cell lung cancer.
  • Has not received systemic antitumor treatment, and is intended to receive monotherapy or combined chemotherapy with a PD-1/PD-L1 inhibitor as first-line treatment.
  • Normal major organ function, that is, meeting the following criteria: (1) Hematological examination criteria must be met: Hb≥90 g/L; ANC≥1.5×10\^9/L; PLT≥80×10\^9/L. (2) Biochemical examination must meet the following criteria: TBIL<1.5×ULN; ALT and AST<2.5×ULN; serum Cr≤1.25×ULN or endogenous creatinine clearance > 45 ml/min (Cockcroft-Gault formula).
  • Women of childbearing age must have taken reliable contraceptive measures and have undergone a pregnancy test (serum or urine) within 7 days before enrollment, with a negative result, and are willing to use appropriate methods of contraception during the trial period and for 8 weeks after the last administration of the trial medication. For men, they must agree to use appropriate methods of contraception during the trial period and for 8 weeks after the last administration of the trial medication or have undergone surgical sterilization.

Exclusion Criteria:

  • Have received any of the following treatments:
  • Previously used any EGFR tyrosine kinase inhibitors;
  • Previously received any chemotherapy for lung cancer;
  • Previously received any radiotherapy for lung cancer (except palliative radiotherapy for bone metastases);
  • Within 4 weeks prior to the first administration of the study drug, the subject had undergone major surgery;
  • Within 7 days prior to the first administration of the study drug, used strong inhibitors or inducers of CYP3A4.
  • Subjects with concurrent other malignant tumors, except for basal cell carcinoma of the skin and in situ cancer.
  • Subjects with uncontrollable malignant pleural effusion and pericardial effusion.
  • Subjects allergic to contrast agents for CT and MRI or any subjects who cannot tolerate MRI examination.
  • As judged by the investigator, any serious or poorly controlled systemic diseases, such as uncontrolled hypertension, active bleeding diathesis, or active infection.
  • Clinically severe gastrointestinal functional abnormalities that may affect the intake, transport, or absorption of the drug, such as the inability to take oral medication, uncontrollable nausea or vomiting, history of extensive gastrointestinal resection, unresolved recurrent diarrhea, atrophic gastritis, gastric diseases requiring long-term use of proton pump inhibitors, Crohn's disease, ulcerative colitis, etc.
  • Hepatic encephalopathy, hepatorenal syndrome, or liver cirrhosis.
  • Meet any of the following cardiac examination results:
  • The average of the corrected QT interval (QTcF) obtained from three ECG examinations at rest is > 470 msec;
  • Resting ECG suggests conduction or ECG morphological abnormalities (such as complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block, and PR interval > 250 msec, etc.);
  • There are any factors that increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concurrent medication of unexplained sudden death in direct relatives under the age of 40 or prolonged QT interval;
  • Left ventricular ejection fraction (LVEF) < 50%.
  • Insufficient bone marrow reserve or organ function, reaching any of the following laboratory limits:
  • Absolute neutrophil count <1.5×10\^9/L;
  • Platelet count <100×10\^9/L;
  • Hemoglobin <90 g/L (<9 g/dL);
  • If there is no definite liver metastasis, alanine aminotransferase > 3 times the upper limit of normal (ULN); if there is liver metastasis, alanine aminotransferase > 5×ULN;
  • If there is no definite liver metastasis, aspartate aminotransferase >3×ULN; if there is liver metastasis, aspartate aminotransferase > 5×ULN;
  • If there is no definite liver metastasis, total bilirubin > 1.5×ULN; or with Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastasis, total bilirubin > 3×ULN;
  • Creatinine > 1.5×ULN and creatinine clearance <50 mL/min (calculated by the Cockcroft-Gault formula); creatinine clearance is only required if creatinine > 1.5×ULN;
  • Serum albumin (ALB) <28 g/L.
  • Active fungal, bacterial, and/or viral infections requiring systemic treatment.
  • Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  • History of interstitial lung disease, drug-induced interstitial lung disease, history of radiation pneumonitis requiring steroid treatment, or any evidence of clinically active interstitial lung disease.
  • Subjects who, in the judgment of the investigator, may have poor compliance with the procedures and requirements of the study, such as subjects with a clear history of neurological or mental disorders, currently suffering from mental disorders, etc.
  • Subjects whom the investigator judges to have any condition that endangers the safety of the subject or interferes with the evaluation of the study.

Quoted from ClinicalTrials.gov, NCT06554613, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06554613, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06554613